Company news

ONO Pharmaceutical Co., Ltd. news in 2026

ONO Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Consolidated Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2027 (IFRS)

October 28, 2026

2nd Quarter of Fiscal Year 2026 (Ending March 31, 2027) (April 1, 2026 to September 30, 2026) Supplementary Materials (Consolidated IFRS)

October 28, 2026

ONO Pharmaceutical: Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN Countries

October 8, 2026

Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN

October 8, 2026

ONO Pharmaceutical: Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures, With or Without Secondary Generalized Seizures

September 16, 2026

Kaneka Ubiquinol™ memenangi nutraingredients Asia Ingredient of the Year: healthspan Award 2026

September 8, 2026

OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO

August 19, 2026

ONO Pharmaceutical: Continues to be Selected for ESG Investment Indexes Adopted by GPIF

August 17, 2026

OPDIVO® Intravenous Infusion Approved in South Korea for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO

August 4, 2026

Consolidated Financial Results for the First Quarter of Fiscal Year Ending March 31, 2027 (IFRS)

July 30, 2026

Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation

July 9, 2026

Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation

June 18, 2026

ONO Pharmaceutical: Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement of Malignant Lymphoma in Patients with Inadequate Response to Existing Therapies or in Whom Such Therapies Are Not Appropriate

June 11, 2026

ONO Pharmaceutical: Pharma Announces Oral Presentation of New Data from Phase 2 Clinical Study of -4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting

June 1, 2026

Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)

May 27, 2026

ONO Pharmaceutical: Pharma Announces Upcoming Presentations at the ASCO 2026 Annual Meeting

April 21, 2026

Notice concerning Introduction of Long-Term Incentive Stock Plan for Employees of Deciphera, the U.S. Subsidiary

March 4, 2026

Notice Concerning Disposal of Treasury Shares by Third-Party Allotment

March 4, 2026

Sinopia Biosciences Announces Target Discovery Collaboration with Ono Pharmaceutical for Rare Metabolic Disorders

March 3, 2026

Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs

March 2, 2026

Announcement on Changes of the Board of Directors and Corporate Officers

March 1, 2026

Announcement concerning the Transfer of Distribution, Sales and Termination of Co-promotion for SGLT2 Inhibitor “Forxiga® 5 mg, 10 mg Tablets’’ in Japan

February 27, 2026

Opdivo® (nivolumab) Intravenous Infusion Approved in South Korea in Combination with Yervoy® (ipilimumab) for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

February 23, 2026

Ono Pharmaceutical Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL

February 16, 2026

Ono Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference Presentation

January 15, 2026

Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

January 14, 2026

Ono to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical

January 7, 2026

Decks in 2026